Jack T. Nguyen
Profile
Jack T.
Nguyen is the founder of Catalyst Bioscience, Inc. Prior to that, he worked as a Research Director at Adamas Pharmaceuticals LLC.
He received a graduate degree from the University of California, Berkeley and a doctorate degree from The University of California, San Francisco.
Former positions of Jack T. Nguyen
| Companies | Position | End |
|---|---|---|
Catalyst Bioscience, Inc. /Old/
 Catalyst Bioscience, Inc. /Old/ Medical SpecialtiesHealth Technology Catalyst Bioscience, Inc. develops and markets catalytic biopharmaceutical products. Its technology consists of methods to identify proteases with tailor-made specificity or improved pharmacological properties. The company was founded by Charles Craik, Sandra Waugh Ruggles and Christopher Thanos in 2003 and is headquartered in South San Francisco, CA. | Founder | - |
| ADAMAS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Jack T. Nguyen
| The University of California, San Francisco | Doctorate Degree |
| University of California, Berkeley | Graduate Degree |
Experiences
Positions held
Linked companies
| Private companies | 2 |
|---|---|
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
Catalyst Bioscience, Inc. /Old/
Catalyst Bioscience, Inc. /Old/ Medical SpecialtiesHealth Technology Catalyst Bioscience, Inc. develops and markets catalytic biopharmaceutical products. Its technology consists of methods to identify proteases with tailor-made specificity or improved pharmacological properties. The company was founded by Charles Craik, Sandra Waugh Ruggles and Christopher Thanos in 2003 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Jack T. Nguyen
